10-Q: Senseonics Holdings Reports First Quarter 2024 Results, Revenue Growth Offset by Increased Expenses

Senseonics Holdings, Inc. reported a revenue increase in the first quarter of 2024, but also experienced a net loss due to higher operating expenses and changes in fair value of derivatives.

Summary

• Senseonics Holdings, Inc. reported a total revenue of $5.0 million for the first quarter of 2024, compared to $4.1 million in the same period of 2023.
• The company's gross profit decreased to $0.3 million, with a gross margin of 6.6%, down from 10.0% in the first quarter of 2023, primarily due to higher fixed manufacturing costs and increased revenue share percentage to Ascensia.
• Operating loss was $18.2 million, compared to $19.7 million in the first quarter of 2023.
• Net loss for the quarter was $18.9 million, compared to a net income of $1.3 million in the first quarter of 2023.
• The company's research and development expenses decreased to $10.4 million, while selling, general, and administrative expenses increased to $8.1 million.
• Senseonics had unrestricted cash, cash equivalents, and marketable securities of $98.7 million as of March 31, 2024.
• The company has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these financial statements are issued.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with revenue growth offset by significant losses and concerns about the company's ability to continue as a going concern. The need for additional funding and the presence of substantial doubt about the company's future viability contribute to a negative sentiment.

Positives

• Total revenue increased by $0.9 million year-over-year, indicating growth in commercial activities.
• Research and development expenses decreased by $2.0 million, primarily due to the completion of 365-day product trials.
• The company secured a $10 million tranche of a loan in January 2024, adding to its cash reserves.

Negatives

• The company experienced a net loss of $18.9 million, a significant decrease compared to the net income of $1.3 million in the same period last year.
• Gross profit decreased to $0.3 million, with a gross margin of 6.6%, down from 10.0% in the same period last year.
• The company's operating loss was $18.2 million, compared to $19.7 million in the first quarter of 2023.
• The company has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these financial statements are issued.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and the need for additional funding.
• The company is subject to a minimum cash covenant and performance covenant under its Loan and Security Agreement.
• The company is dependent on the successful commercialization and adoption of its Eversense CGM systems.
• The company is subject to patent litigation, which could be costly and disruptive.
• The company relies heavily on one customer, Ascensia, for a significant portion of its revenue.

Future Outlook

The company anticipates that its principal uses of cash in the future will be primarily to fund its operations, working capital needs, capital expenditures and other strategic initiatives. The company's ability to continue to fund its operations and meet capital needs will depend on its ability to successfully obtain funding from public or private debt and equity financings and other sources of capital.

Management Comments

• Management has determined that substantial doubt exists regarding its ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.
• The company will require additional liquidity to continue its operations over the next 12 months and is currently evaluating strategies to obtain the required additional funding for future operations.

Industry Context

The medical device industry, particularly the glucose monitoring sector, is characterized by intense competition and frequent patent litigation. Senseonics is navigating this landscape while also working to expand market adoption of its implantable CGM technology. The company's reliance on a single major customer, Ascensia, also highlights the importance of strategic partnerships in this industry.

Comparison to Industry Standards

• Senseonics' gross margin of 6.6% is significantly lower than the industry average for medical device companies, which typically ranges from 50% to 70%.
• Competitors like Dexcom and Abbott, which focus on non-implantable CGMs, generally have higher gross margins due to their established manufacturing processes and larger sales volumes.
• Senseonics' high operating expenses, particularly in R&D and SG&A, are typical for companies in the early commercialization stages of innovative medical technologies.
• The company's reliance on debt financing and the need for additional capital raises are common among smaller medical device companies that are still working towards profitability.
• The company's focus on long-term implantable CGM technology differentiates it from competitors, but also presents unique challenges in terms of regulatory approvals, market adoption, and reimbursement.

Legal Proceedings

• The company is involved in a patent infringement lawsuit filed by Cellspin Soft, Inc.
• The company successfully defended against a False Claims Act lawsuit, with the Fifth Circuit affirming the dismissal of the plaintiff's claims.

Related Party Transactions

• The company derived 88% of its total revenue from Ascensia in Q1 2024.
• The company purchases certain medical supplies from Ascensia for its clinical trials.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be concerned about job security given the company's financial challenges.
• Customers and healthcare providers may be concerned about the long-term availability of the Eversense system.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company will continue to monitor its capital structure and market conditions.
• The company will evaluate strategies to obtain the required additional funding for future operations.
• The company will continue to develop and commercialize its Eversense CGM systems.

Key Dates

Keywords

Eversense, CGM, Continuous Glucose Monitoring, Diabetes, Medical Device, Implantable Sensor, Ascensia, Revenue, Net Loss, Financial Results